Transaction #27914 · Form 4 · 0001171780-26-000002
AbbVie Inc. · Stock award · Stock Equivalent Units
AbbVie Inc. · Transacted December 31, 2025 · Filed January 5, 2026
What does this filing report?
An SEC Form 4 filing for AbbVie Inc. records a stock award involving Stock Equivalent Units on December 31, 2025. The reported quantity was 147. The filing date is January 5, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- AbbVie Inc.
- Company CIK
- 0001551152
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 147
- Reported price
- 228.49
- Reference value
- 33,588.03
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 28,498
- Ownership description
- Not reported
- SEC acceptance time
- Jan 5, 2026, 5:00 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- RAPP EDWARD J ↗
Director
CIK 0001171780
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 147
- Conversion / exercise price
- 228.49
- Exercise date
- Not reported
- Expiration date
- Not reported
Filing footnotes & remarks
- F1
- Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.
- F2
- Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.